Large international study highlights antibiotic resistance challenge in people with chronic lung conditions

Published on 20 November 2026

A recent international study has found that people with chronic lung disease, including bronchiectasis and cystic fibrosis (CF), have a high burden of antimicrobial resistance, with variation by geographic location that can persist even after targeted therapies.  

Published in the BMJ journal Thorax and led by Dr Anand Shah, consultant respiratory physician at Royal Brompton and Harefield Hospitals, the study was conducted as part of the European Respiratory Society AMR-Lung clinical research collaboration. It is the largest analysis of antimicrobial resistance in chronic lung disease globally to date.

Antimicrobial resistance (AMR) is the ability of microorganisms such as bacteria, fungi and viruses to adapt when treated with antimicrobial drugs, such as antibiotics. 
Chronic lung infection (CLI) is common in patients with respiratory airway diseases such as bronchiectasis, including individuals with CF.

Bronchiectasis is a condition in which the body produces thick, sticky mucus that lines the airways, resulting in airways (bronchial tubes) that are permanently widened or damaged. CF is the most common genetic cause of bronchiectasis globally.

As a result, people with these conditions often require repeated or long-term antibiotic treatment, which can increase the risk of infections caused by antimicrobial-resistant bacteria.

Despite the existing understanding that people living with CLI are particularly vulnerable to AMR, there had previously been no international analyses examining the scale and patterns of antimicrobial resistance in this patient group.

In this study, researchers analysed 110,323 respiratory samples from more than 19,000 people with bronchiectasis or CF. These samples were collected from 11 cities across 3 continents between 2011 and 2024.

The team looked at bacteria present in these samples and assessed patterns of antimicrobial resistance, including resistance to multiple antibiotics, across different diseases and countries.

The study found that among people with and bronchiectasis, there were geographic differences in AMR, with different pathogens presenting a higher burden of resistance in Europe compared with regions in Asia such as Hong Kong.

This means that the bacteria causing infections, and their response to antibiotics, may vary depending on where patients live, highlighting the importance of ongoing monitoring and tailored treatment approaches.

The study also found that antimicrobial resistance remained a significant challenge among some people with CF receiving cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. This suggests that, despite major advances in treatment, resistant infections may continue to affect a proportion of patients.

Overall, the study found substantial geographic variation in the bacteria causing chronic lung infections and a high burden of antimicrobial resistance in both bronchiectasis and CF.

The findings highlight the importance of continued international monitoring of antimicrobial resistance and support the team's ongoing work to develop a prospective registry for people living with chronic lung infection.

When asked about this research, Dr Shah stated:

“Antimicrobial resistance is a global emergency and is a particular problem for individuals with chronic lung disease. Current international AMR surveillance systems are focused on blood-related infections so don’t capture the burden in lung disease.

“This research is important to showcase the scale of the problem in lung disease so that we can identify novel strategies for AMR detection, understand how best to use antibiotics and consider novel therapeutic approaches to treat lung infection.”